Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

A clinical study of Evenamide (NW-3509) in patients with schizophrenia experiencing worsening of psychosis on atypical antipsychotics

Trial Profile

A clinical study of Evenamide (NW-3509) in patients with schizophrenia experiencing worsening of psychosis on atypical antipsychotics

Planning
Phase of Trial: Phase III

Latest Information Update: 13 Sep 2018

At a glance

  • Drugs Evenamide (Primary)
  • Indications Schizophrenia
  • Focus Registrational; Therapeutic Use
  • Sponsors Newron Pharmaceuticals
  • Most Recent Events

    • 13 Sep 2018 According to a Newron Pharmaceuticals media release, this study is expected to commence in H1 2019.
    • 01 Mar 2018 According to a Newron Pharmaceuticals media release, this study is expected to commence towards the end of 2018.
    • 11 Dec 2017 According to a Newron Pharmaceuticals media release, this study expected to start in early 2018.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top